Avonza - Tenofovir Disoproxil Fumarate, Lamivudine, and Efavirenz Tabs

This fixed-dose combination brings together two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), Tenofovir Disoproxil Fumarate and Lamivudine, along with a non-nucleoside reverse transcriptase inhibitor (NNRTI), Efavirenz, forming a complete antiretroviral regimen in a single tablet. These three agents work at different stages of the HIV replication cycle, and their combined action helps more effectively lower viral load while reducing the likelihood of drug resistance developing. As viral activity is suppressed, the immune system is given a better chance to recover, often reflected in improved CD4 cell counts over time. Being available as a single-tablet, once-daily regimen, this combination can make it easier for patients to maintain consistent adherence, which is essential for sustained treatment success. It is generally recommended to be taken on an empty stomach, often at bedtime, to help minimize certain side effects associated with Efavirenz. Regular monitoring, including blood tests for viral load, CD4 counts, and kidney and liver function, is typically recommended throughout treatment. Many patients using this combination achieve durable viral suppression and meaningful improvements in overall immune health. As with all antiretroviral therapies, it should be used under the guidance of a healthcare provider as part of a comprehensive, personalized HIV care plan.